<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391221</url>
  </required_header>
  <id_info>
    <org_study_id>2011005</org_study_id>
    <nct_id>NCT01391221</nct_id>
  </id_info>
  <brief_title>Inflammatory Markers and Cognitive Function in Major Depression</brief_title>
  <official_title>Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major depression is accompanied by cognitive changes as well as alterations in multiple
      physical functions. The inflammatory system is altered generally toward a pro-inflammatory
      state. Antidepressants are associated with a decrease in this proinflammatory state. This
      study aims to generate pilot data concerning a possible link between cognition, inflammation
      and response to treatment. The cognitive function of subjects with major depression will be
      tested before and after treatment with duloxetine. Inflammatory markers will be measured at
      both time points.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive function measured by CANTAB</measure>
    <time_frame>12 weeks</time_frame>
    <description>Correlation between cytokines and cognitive function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain inhibition</measure>
    <time_frame>12 weeks</time_frame>
    <description>Correlation between depression, antidepressant treatment status, inflammation and inhibition of perception of pain stimulus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allostatic load</measure>
    <time_frame>12 weeks</time_frame>
    <description>Correlation between depressive symptoms, antidepressant treatment status and allostatic load</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>Duloxetine treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with major depression will be entered into the trial and treated with open label duloxetine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention</description>
    <arm_group_label>Duloxetine treatment</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-50 Primary diagnosis of major depression Ability to give informed consent

        Exclusion Criteria:

          -  Neurologic disorders affecting cognition

          -  Unstable or untreated medical disorders

          -  Medical disorders associated with pain

          -  Recent pregnancy or delivery

          -  Psychiatric disorders other than MD which are the primary focus of treatment

          -  Treatment with antidepressants in the past 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Louise Normandeau, Nursing</last_name>
    <phone>514-251-4000</phone>
    <phone_ext>3535</phone_ext>
    <email>urb.crfs@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Souad Lhalafi, Nursing</last_name>
    <phone>514-251-4000</phone>
    <phone_ext>3416</phone_ext>
    <email>urb.crfs@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Recherche Fernand Seguin</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1N3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Normandeau, nursing</last_name>
      <phone>514-251-4000</phone>
      <phone_ext>3535</phone_ext>
      <email>urb.crfs@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Souad Lhalafi, nursing</last_name>
      <phone>514-251-4000</phone>
      <phone_ext>3416</phone_ext>
      <email>urb.crfs@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Valerie S Tourjman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edouard Kouassi, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephane Potvin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierrich Pusquellech, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert-Paul Juster, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Eve Koue, MSc</last_name>
    </contact>
    <investigator>
      <last_name>Jacques Bernier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2011</study_first_submitted>
  <study_first_submitted_qc>July 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2011</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine</investigator_affiliation>
    <investigator_full_name>Smadar Valerie Tourjman</investigator_full_name>
    <investigator_title>MDCM, FRCPc, MSc</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Cognition</keyword>
  <keyword>Pain</keyword>
  <keyword>Allostatic load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

